Glioblastoma News and Research

RSS
Glioblastoma is the most aggressive and malignant form of glioma, a type of primary brain cancer. Surgery is often used to treat gliomas, along with radiation. However, since surgery and radiation fail to cure the disease, doctors may turn to additional radiation or chemotherapy. In early stages glioblastoma tumors often grow without symptoms and therefore can become quite large before symptoms arise. When the tumor becomes symptomatic, tumor growth is usually very rapid and is accompanied by altered brain function, and if left untreated the disease becomes lethal. Although primary treatment is often successful in temporarily stopping the progression of the tumor, glioblastomas almost always recur and become lethal.
ImmunoCellular Therapeutics' dendritic cell-based vaccination with CSCs demonstrates survival benefits

ImmunoCellular Therapeutics' dendritic cell-based vaccination with CSCs demonstrates survival benefits

Exelixis fourth-quarter revenues rise from $29.6M to $44.1M

Exelixis fourth-quarter revenues rise from $29.6M to $44.1M

Clinical and scientific advances made in the field of neuro-oncology

Clinical and scientific advances made in the field of neuro-oncology

Rexahn Pharmaceuticals granted Japanese patent for Archexin

Rexahn Pharmaceuticals granted Japanese patent for Archexin

Celldex Therapeutics reports net loss of $13.5M for fourth-quarter of 2009

Celldex Therapeutics reports net loss of $13.5M for fourth-quarter of 2009

Geron highlights telomerase inhibitor's activity against cancer stem cells at AACR Special Conference

Geron highlights telomerase inhibitor's activity against cancer stem cells at AACR Special Conference

ImmunoCellular Therapeutics receives Notice of Allowance on ICT-69 monoclonal antibody

ImmunoCellular Therapeutics receives Notice of Allowance on ICT-69 monoclonal antibody

Brain cancer awareness: 55-year-old cycles across USA

Brain cancer awareness: 55-year-old cycles across USA

Notch-blocking drug effective against brain cancer stem cells, but more than one targeted attack needed

Notch-blocking drug effective against brain cancer stem cells, but more than one targeted attack needed

AGH neurosurgeons explore new therapeutic approach for brain tumor

AGH neurosurgeons explore new therapeutic approach for brain tumor

Antigenics announces fourth-quarter and full-year 2009 financial results

Antigenics announces fourth-quarter and full-year 2009 financial results

World's smallest ultrasound device could offer a new level of home therapy for painful ailments

World's smallest ultrasound device could offer a new level of home therapy for painful ailments

Cancer Research UK, immatics Biotechnologies sign collaboration agreement to trial IMA950 vaccine for GMB

Cancer Research UK, immatics Biotechnologies sign collaboration agreement to trial IMA950 vaccine for GMB

Viral Genetics: Company update

Viral Genetics: Company update

Peregrine Pharmaceuticals' Cotara specifically targets solid tumors and anti-tumor activity

Peregrine Pharmaceuticals' Cotara specifically targets solid tumors and anti-tumor activity

Second-quarter fiscal 2010 results announced by Pharmacyclics

Second-quarter fiscal 2010 results announced by Pharmacyclics

YM Biosciences to present JAK1/2 inhibiting small molecule and vascular disrupting agent data at Cancer Conference

YM Biosciences to present JAK1/2 inhibiting small molecule and vascular disrupting agent data at Cancer Conference

Market Media Connect retained as Northwest Biotherapeutics' communications agency of record

Market Media Connect retained as Northwest Biotherapeutics' communications agency of record

Pfizer, DxS sign agreement to develop a diagnostic test kit for CDX-110 to treat patients with GBM

Pfizer, DxS sign agreement to develop a diagnostic test kit for CDX-110 to treat patients with GBM

YM BioSciences-Cytopia merger complete

YM BioSciences-Cytopia merger complete

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.